


## Original Investigation | CARING FOR THE CRITICALLY ILL PATIENT

# Induced Hypothermia in Severe Bacterial Meningitis

## A Randomized Clinical Trial

Bruno Mourvillier, MD; Florence Tubach, MD, PhD; Diederik van de Beek, MD, PhD; Denis Garot, MD; Nicolas Pichon, MD; Hugues Georges, MD; Laurent Martin Lefevre, MD; Pierre-Edouard Bollaert, MD; Thierry Boulain, MD; David Luis, MD; Alain Cariou, MD; Patrick Girardie, MD; Riad Chelha, MD; Bruno Megarbane, MD, PhD; Arnaud Delahaye, MD; Ludivine Chalumeau-Lemoine, MD; Stéphane Legriel, MD; Pascal Beuret, MD; François Brivet, MD; Cédric Bruel, MD; Fabrice Camou, MD; Delphine Chatellier, MD; Patrick Chillet, MD; Bernard Clair, MD; Jean-Michel Constantin, MD; Alexandre Duguet, MD; Richard Galliot, MD; Frédérique Bayle, MD; Hervé Hyvemat, MD; Kader Ouchenir, MD; Gaetan Plantefeve, MD; Jean-Pierre Quenot, MD; Jack Richecoeur, MD; Carole Schwebel, MD; Michel Sirodot, MD; Marina Esposito-Farèse, PhD; Yves Le Tulzo, MD, PhD; Michel Wolff, MD

 Supplemental content at [jama.com](http://jama.com)

**IMPORTANCE** Despite advances in care, mortality and morbidity remain high in adults with acute bacterial meningitis, particularly when due to *Streptococcus pneumoniae*. Induced hypothermia is beneficial in other conditions with global cerebral hypoxia.

**OBJECTIVE** To test the hypothesis that induced hypothermia improves outcome in patients with severe bacterial meningitis.

**DESIGN, SETTING, AND PATIENTS** An open-label, multicenter, randomized clinical trial in 49 intensive care units in France, February 2009–November 2011. In total, 130 patients were assessed for eligibility and 98 comatose adults (Glasgow Coma Scale [GCS] score of  $\leq 8$  for <12 hours) with community-acquired bacterial meningitis were randomized.

**INTERVENTIONS** Hypothermia group received a loading dose of 4°C cold saline and were cooled to 32°C to 34°C for 48 hours. The rewarming phase was passive. Controls received standard care.

**MAIN OUTCOMES AND MEASURES** Primary outcome measure was the Glasgow Outcome Scale score at 3 months (a score of 5 [favorable outcome] vs a score of 1-4 [unfavorable outcome]). All patients received appropriate antimicrobial therapy and vital support. Analyses were performed on an intention-to-treat basis. The data and safety monitoring board (DSMB) reviewed severe adverse events and mortality rate every 50 enrolled patients.

**RESULTS** After inclusion of 98 comatose patients, the trial was stopped early at the request of the DSMB because of concerns over excess mortality in the hypothermia group (25 of 49 patients [51%]) vs the control group (15 of 49 patients [31%]; relative risk [RR], 1.99; 95% CI, 1.05-3.77;  $P = .04$ ). Pneumococcal meningitis was diagnosed in 77% of patients. Mean (SD) temperatures achieved 24 hours after randomization were 33.3°C (0.9°C) and 37.0°C (0.9°C) in the hypothermia and control group, respectively. At 3 months, 86% in the hypothermia group compared with 74% of controls had an unfavorable outcome (RR, 2.17; 95% CI, 0.78-6.01;  $P = .13$ ). After adjustment for age, score on GCS at inclusion, and the presence of septic shock at inclusion, mortality remained higher, although not significantly, in the hypothermia group (hazard ratio, 1.76; 95% CI, 0.89-3.45;  $P = .10$ ). Subgroup analysis on patients with pneumococcal meningitis showed similar results. Post hoc analysis showed a low probability to reach statistically significant difference in favor of hypothermia at the end of the 3 planned sequential analyses (probability to conclude in favor of futility, 0.977).

**CONCLUSIONS AND RELEVANCE** Moderate hypothermia did not improve outcome in patients with severe bacterial meningitis and may even be harmful. Careful evaluation of safety issues in future trials on hypothermia are needed and may have important implications in patients presenting with septic shock or stroke.

**TRIAL REGISTRATION** [clinicaltrials.gov](http://clinicaltrials.gov) Identifier: NCT00774631

JAMA. doi:10.1001/jama.2013.280506  
Published online October 8, 2013.

**Author Affiliations:** Author affiliations are listed at the end of this article.

**Corresponding Author:** Bruno Mourvillier, MD, Réanimation Médicale et Infectieuse, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Bichat-Claude Bernard 46, Rue Henri Huchard, 75018 Paris, France (bruno.mourvillier@bch.aphp.fr).

Among adults with bacterial meningitis, the case fatality rate and frequency of neurologic sequelae are high, especially among patients with pneumococcal meningitis.<sup>1-3</sup> Although adjunctive dexamethasone therapy has been shown to benefit adults with pneumococcal meningitis,<sup>4,5</sup> case fatality remains 20%, stressing the need for new therapeutic approaches.<sup>6</sup> In animal models of meningitis, moderate hypothermia has favorable effects, such as lowering intracranial pressure, modulating nuclear factor- $\kappa$ B activation, preventing apoptosis, and possibly reducing cerebral injury.<sup>7-10</sup> Therapeutic hypothermia<sup>11</sup> is widely applied in global cerebral hypoxemia, such as postcardiac arrest, following evidence of beneficial effects in controlled prospective trials.<sup>12-15</sup> By contrast, hypothermia is less commonly used in traumatic brain injury, where studies have shown conflicting results.<sup>16,17</sup> Clinical trials of patients with trauma have shown a decrease of intracranial pressure in those patients treated with hypothermia, stressing the potential benefit of this technique in bacterial meningitis. Randomized trials on the efficacy and safety of moderate hypothermia in meningitis are lacking, but favorable results of experimental studies and case reports have encouraged clinicians to perform hypothermia in the most severe cases.<sup>18</sup> Lepur et al<sup>19</sup> reported hypothermia in 10 patients with severe bacterial meningitis. In this study, core temperature of patients was lowered between 32°C and 34°C for 72 to 96 hours, with 8 patients having favorable outcomes.

We hypothesized that treatment with hypothermia (32°C-34°C for 48 hours) would improve the functional outcome at 3 months compared with standard care without systemic hypothermia in comatose patients (defined as having a Glasgow Coma Scale[GCS] score of  $\leq 8$  for  $<12$  hours) with bacterial meningitis.

## Methods

### Patients and Sites

We conducted this sequential, open-label, multicenter, randomized controlled trial at 49 intensive care units in France. All sites are routinely using hypothermia for patients after cardiac arrest. Patients were eligible if they were aged at least 18 years and had a suspected or proven bacterial meningitis by either (1) cerebrospinal fluid (CSF) white blood cell count of more than 100/ $\mu$ L and glucose CSF/blood ratio of less than one-third, (2) a CSF protein concentration of more than 2.2 g/L or microorganisms observed in CSF Gram stain, (3) a positive soluble antigen test or polymerase chain reaction for *Streptococcus pneumoniae* or *Neisseria meningitidis*, or (4) positive CSF cultures. All patients had a score on the GCS of 8 or lower for less than 12 hours and had received appropriate antimicrobial therapy. Appropriate antimicrobial therapy was defined as intravenous cefotaxime (200-300 mg/kg/d) or ceftriaxone (100 mg/kg/d); in case of suspicion of listeriosis, amoxicillin was added.

Patients were excluded if they were pregnant, had a positive cryptococcal test, brain abscess, purpura fulminans, or complications requiring therapeutic hypothermia, such as cardiac arrest. Patients were also excluded if the physician in

charge decided to limit life support, if the patient had no medical insurance, or if they were included in another interventional study.

The study received ethics approval by CPP Ile de France I, Paris-Hôtel Dieu, Paris, France. The trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practices and adhered to the French regulatory requirements. Written informed consent was obtained from patient surrogates before study inclusion. However, according to French law, in the case of impaired decision making capacity without any surrogate at the time of inclusion, the patient's written informed consent could be obtained after enrollment.

### Randomization and Patient Care

Randomization was centralized via the trial website, balanced by blocks of variable and undisclosed size, and stratified on the hypothermia technique (intravascular cooling vs other cooling techniques). In the hypothermia group, patients received a loading dose of 4°C cold saline. We used the protocol previously published by Polderman et al,<sup>20</sup> in which 1500 mL of refrigerated (4°C-6°C) fluids were infused over a 30-minute period. If temperatures had decreased to 33.5°C or lower, no additional refrigerated fluids were infused. If temperatures remained at more than 33.5°C, an additional 500 mL of refrigerated fluid was infused over a 10-minute period. This was repeated until temperatures had reached levels of 33.5°C or higher.<sup>20</sup> All centers were used to routine hypothermia techniques. Esophageal temperature was maintained between 32°C and 34°C for 48 hours with the technique that was used routinely by that particular center. The rewarming phase was strictly passive.


All patients were treated according to guidelines established according to published guidelines and expert opinions.<sup>2,21,22</sup> These recommendations (see eAppendix 1 in the Supplement) included appropriate antimicrobial therapy, mean arterial pressure maintained at more than 70 mm Hg, normocapnia, glycemia of less than 8 mmol/L, natremia between 140 to 145 mmol/L, magnesemia in normal range (0.75-1.00 mmol/L), and phosphoremia of more than 0.6 mmol/L.

We documented baseline characteristics and other parameters during the first week, including nosocomial infections, hemorrhage, cardiovascular complications, and hyperglycemia (eAppendix 2 in the Supplement). Routine electroencephalography was performed after 24 or 48 hours.

### Study Outcome Measures

The primary outcome measure was the score on the Glasgow Outcome Scale (GOS) 3 months after randomization<sup>23</sup> as assessed by an independent physician blinded from the treatment regimen (Prospective Randomized Open Blinded Endpoint methodology)<sup>24</sup> by means of a telephone structured interview.<sup>25,26</sup> A score of 1 indicated death; score of 2, a vegetative state; score of 3, severe disability; score of 4, moderate disability; and score of 5, mild or no disability.<sup>25,26</sup> As previously reported in meningitis,<sup>3,4</sup> favorable outcome was defined as a score of 5, and an unfavorable outcome as a score of 1 to 4.

Figure 1. Flow Diagram of Patients



GCS indicates Glasgow Coma Scale.  
<sup>a</sup>Other reasons for exclusion were pregnancy, positive cryptococcal test result, brain abscess, or complications requiring therapeutic hypothermia, such as cardiac arrest. Patients were also excluded if the physician in charge decided to limit life support, if the patient had no medical insurance, or if the individual was included in another interventional study. Among these 7 excluded, 2 patients were missed.

Secondary end points were overall mortality at 3 months, hearing impairment at 3 months using the whispered voice test,<sup>27</sup> muscle strength assessed by the Medical Research Council score at intensive care discharge and 3 months posttreatment, complications during the first 7 days after randomization and weekly afterwards over 28 days, and GOS at 6 months. Three investigators (B.M., D.v.d.B., and M.W.), who were masked to the randomization assignment, reviewed all patient charts who died and determined causes of death by consensus, as described previously.<sup>28</sup>

### Statistical Analysis

The trial was designed as a triangular sequential study.<sup>29</sup> Unfavorable outcome was expected in 35% of patients with severe meningitis.<sup>1-3</sup> We expected a 15% absolute risk reduction based on previous results of hypothermia after cardiac arrest<sup>5</sup> and dexamethasone in bacterial meningitis.<sup>3</sup> With a 2-sided  $\alpha = .05$  and a statistical power of 80%, a total sample size of 276 patients was required. This hypothesis involved a relatively small number of meningitis cases. If a larger sample size had been planned, trial completion would have taken an unrealistically long time with excessive costs. As severe meningitis is a relatively rare disease, 3 interim analyses were planned after 106, 212, and 318 patients were enrolled, respectively. Preset boundaries would permit termination of the trial if the hypothermia group was found to be better than, less than, or equal to the control group.

To address potential safety issues for this new indication of therapeutic hypothermia, the data and safety monitoring board (DSMB) asked to review severe adverse events and mortality rate in both groups for every 50 enrolled patients. Because the number of patients required for the first interim analysis had not been reached, the proportion of patients with an unfavorable outcome was compared between groups by a  $\chi^2$  test, according to the intention-to-treat principle. For 1 pa-

tient included in the hypothermia group, the GOS score at 3 months was not available because the patient was transferred to a nonparticipating center; therefore, data at 6 months was used (GOS score, 4). Health care proxy withdrew consent after 2 days for 1 patient in the control group who died on day 6. Data from the first 2 days and outcome were kept for analysis. These 2 patients were included in the final analysis. In addition, the primary favorable outcome at 3 months was analyzed with a double triangular sequential design.<sup>29</sup> Post hoc analysis, given observed data from the 98 randomized patients and preplanned assumptions, provided the probabilities to conclude in favor of the hypothermia group, in favor of the control group, and the probability to conclude in favor of futility if the trial had proceeded to completion.

Secondary analyses regarding survival were performed with the Cox proportional hazards regression model. We determined survival curves according to the Kaplan Meier method. Serum sodium concentrations over time were analyzed by using linear mixed models with patient as a random variable. We tested the effect of the interaction of time  $\times$  treatment group to test sodium concentrations over time by treatment groups. Because we anticipated that pneumococcal meningitis would represent 80% of the total number of enrolled patients, a subgroup analysis of these patients was planned a priori. Analyses were performed with a 2-sided significance level of .05 with R software version 15.1.

## Results

Between February 2009 and November 2011, 130 patients were evaluated for inclusion and 32 were excluded from the study (Figure 1). After randomization of 98 patients (49 in each group), the trial was stopped early by the DSMB because of a higher mortality at 3 months in the hypothermia group than in the

control group (25 patients [51%] vs 15 patients [31%] died, respectively; relative risk, 1.99; 95% CI, 1.05-3.77;  $P = .04$ ). Mortality difference was not a prespecified stopping rule. Interim analyses were planned on the main outcome criterion only. The first interim analysis was planned after 106 patients were enrolled. The DSMB analysis revealed that the difference in mor-

tality at 3 months between the 2 groups was statistically significant (univariate Cox proportional hazards regression model,  $P = .04$ ). Post hoc analysis, given observed data from the 98 randomized patients and preplanned assumptions, showed that the probability to reach statistical significance in favor of hypothermia was very low if the trial had proceeded to completion (probability to conclude in favor of hypothermia group, 0.023; probability to conclude in favor of control group,  $<.001$ ; and probability to conclude in favor of futility, 0.977), supporting the DSMB decision (eAppendix 3 in the Supplement).

No significant differences between treatment groups with respect to baseline characteristics was observed (Table 1). All patients received mechanical ventilation and were severely ill as reflected by a median score of 7 on the GCS in both groups and high median Simplified Acute Physiology Score II (SAPS II) scores (53 in the control group and 57 in the intervention group). The Simplified Acute Physiology Score ranged from 0 to 154, with higher SAPS II scores indicating more severe illness. A causative bacterium was detected in 90 of 98 patients (92%) and *S pneumoniae* was the most common pathogen, causing disease in 75 of 98 patients (77%). Eight patients presented with coexisting pneumonia. Septic shock at baseline occurred in 18 patients (37%) in the hypothermia group and 10 patients (20%) in the control group ( $P = .14$ ). Sepsis in these 28 patients was considered to be caused by the microorganism responsible for meningitis. The study included 49 centers, but only 34 centers were active, with a median of randomized patients of 1.

### Intervention

Cooling began in the hypothermia group immediately after randomization. Patients reached the goal temperature within a median (interquartile range [IQR]) time of 4.4 hours (2-8 hours) (Figure 2) after a median (IQR) cold saline volume of 2401 mL (1500-3125 mL). None of the patients assigned to the control group was treated with hypothermia. We compared patients who received a loading volume of lesser than the median with those who received volumes higher than the median. Mortality (14 of 49 patients [29%] vs 11 of 49 patients [22%]; by  $t$  test,  $P = .34$ ) and scores on the GOS (by Fisher test,  $P = .90$ ) at 3 months did not differ between patients who received high vs low loading volumes.

Mean (SD) temperatures achieved 24 hours after randomization were 33.3°C (0.9°C) in the hypothermia group and 37.0°C (0.9°C) in the control group. In the hypothermia group, 13 patients were cooled with intravascular technique, 11 with ice packs and cooling air, 10 with ice packs alone, 7 with cooling air alone, 4 with cooling pads, 3 with cooling mattress, and 1 with internal cooling. Hypothermia was stopped before 48 hours after randomization in 7 patients because of death ( $n = 2$ ), acute myocardial infarction ( $n = 1$ ), severe bradycardia ( $n = 1$ ), anisocoria ( $n = 1$ ), a head computed tomography scan ( $n = 1$ ), and referral to a nonparticipating center for neurosurgery ( $n = 1$ ). The body temperature of the patient for whom hypothermia was stopped because of a head computed tomography scan remained within the 32°C to 34°C range. Overall, median (IQR) time of passive rewarming to a body temperature of more than 36°C was 14 hours (8-111 hours).

Table 1. Baseline Characteristics of the Patients

| Characteristics   | Hypothermia Group<br>(n = 49) | Control Group<br>(n = 49) |
|---|-------------------------------|---------------------------|
| Age, mean (SD), y   | 59 (18)                       | 59 (17)                   |
| Male sex, No. (%)   | 28 (57)                       | 31 (63)                   |
| GCS score on ICU admission, median (IQR), h <sup>a</sup>        | 7 (4-8)                       | 7 (6-8)                   |
| SAPS II score, mean (SD) <sup>b</sup>                           | 57 (16)                       | 53 (17)                   |
| SOFA score, mean (SD) <sup>c</sup>                              | 9 (3)                         | 8 (4)                     |
| Mechanical ventilation, No. (%)                                 | 49 (100)                      | 49 (100)                  |
| Septic shock, No. (%)   | 18 (37)                       | 10 (20)                   |
| Pneumonia, No. (%)  | 3 (6)                         | 5 (10)                    |
| CSF leukocyte count, / $\mu$ L                                  |                               |                           |
| Mean (SD)   | 4342 (9601)                   | 3678 (5457)               |
| Median (range)  | 890 (6-60 000)                | 1150 (4-23 400)           |
| Protein, mean (SD), g/L   | 5.8 (4)                       | 7 (4)                     |
| Glucose, median (IQR), mg/dL                                    | 0.22 (0.01-0.78)              | 0.10 (0.00-1.18)          |
| Lactate, mean (SD), mg/dL                                       | 139.64 (90.09)                | 144.14 (54.05)            |
| CSF culture results, No. (%)                                    |                               |                           |
| <i>Streptococcus pneumoniae</i>                                 | 37 (76)                       | 38 (78)                   |
| <i>Streptococcus bovis</i>                                      | 1 (2)                         | 0                         |
| <i>Neisseria meningitidis</i>                                   | 2 (4)                         | 6 (12)                    |
| <i>Listeria monocytogenes</i>                                   | 1 (2)                         | 2 (4)                     |
| Enterobacteriaceae  | 3 (6)                         | 0                         |
| <i>Mycobacterium tuberculosis</i>                               | 1 (2)                         | 0                         |
| None  | 5 (10)                        | 3 (6)                     |
| Positive soluble antigen, No. (%) <sup>d</sup>                  | 19 (40)                       | 24 (50)                   |
| Positive culture, No. (%) <sup>d</sup>                          | 23 (48)                       | 20 (42)                   |
| Positive PCR, No. (%) <sup>d</sup>                              | 6 (13)                        | 4 (8)                     |
| Corticosteroids, No. (%)  | 43 (88)                       | 42 (87)                   |
| Dexamethasone, No. (%)  | 38 (78)                       | 39 (81)                   |
| Time, median (IQR), h   |                               |                           |
| Hospital admission to first antibiotic dose                     | 3.0 (1.1-4.8)                 | 2.6 (1.4-4.9)             |
| Hospital admission to first dose of corticosteroid <sup>e</sup> | 5.8 (2.5-8.8)                 | 4.3 (2.3-7.9)             |
| Sedative drugs, No. (%)   | 14 (29)                       | 13 (27)                   |

Abbreviations: CSF, cerebrospinal fluid; GCS, Glasgow Coma Scale; ICU, intensive care unit; IQR, interquartile range; PCR, polymerase chain reaction; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment.

SI conversions: To convert glucose to mmol/L, multiply by 0.0555; to convert lactate to mmol/L, multiply by 0.111.

<sup>a</sup> Scores on the GCS range from 3 to 15, with 15 indicating a normal level of consciousness.

<sup>b</sup> Scores on the SOFA range from 0 to 4 for each organ system, with higher scores indicating more severe organ dysfunction.

<sup>c</sup> Scores on the SAPS range from 0 to 154, with higher SAPS II scores indicating more severe illness.

<sup>d</sup> Number of patients evaluated was 96 (48 in each group).

<sup>e</sup> Number of patients evaluated was 95 (43 in the hypothermia group and 42 in the control group).


**Efficacy and Safety**

At 3 months, unfavorable outcome occurred in 42 of 49 patients (86%) in the hypothermia group and 36 of 49 patients (73%) in the control group (risk ratio, 1.17; 95% CI, 0.95-1.43; *P* = .13) (Table 2).

The distribution of scores on the GOS is shown in Table 2 and Figure 3. At 3 months, mortality was significantly higher in the hypothermia group (hazard ratio [HR], 1.99; 95% CI, 1.05-3.77; log-rank *P* = .04) (eTable 1 in the Supplement). In a mul-

tivariable Cox proportional hazards regression analysis after adjustment for age, score on GCS at inclusion, and the presence of septic shock at inclusion, mortality remained higher, although not significantly, in the hypothermia group (HR, 1.76; 95% CI, 0.89-3.45; *P* = .10) (Table 3). Figure 4 shows survival data for patients treated with hypothermia and patients in the control group. Variables used in the Cox proportional hazards regression model were selected a priori because they were clinically relevant and after examination of the data. Unfavorable

**Figure 2. Body Temperature of Patients With Severe Meningitis During First 48 Hours After Randomization Between Hypothermia and Standard Therapy**



**Table 2. Primary and Secondary Outcomes at 3 Months in the Hypothermia and Control Groups (N=98)**

| Outcome                                      | No. (%) of Patients        |                        | Risk Ratio (95% CI) | P Value |
|--|----------------------------|------------------------|---------------------|---------|
|  | Hypothermia Group (n = 49) | Control Group (n = 49) |                     |         |
| Unfavorable outcome (score on GOS <5)        | 42 (86)                    | 36 (74)                | 1.17 (0.95-1.43)    | .13     |
| GOS score                                    |                            |                        |                     |         |
| 5 = mild or no disability                    | 7 (14)                     | 13 (27)                | 1 [Reference]       | .04     |
| 4 = moderate disability                      | 10 (20)                    | 6 (12)                 | 1.49 (0.69-3.23)    |         |
| 3 = severe disability                        | 7 (14)                     | 15 (31)                | 0.23 (0.13-0.44)    |         |
| 2 = vegetative state                         | 0                          | 0                      |                     |         |
| 1 = death                                    | 25 (51)                    | 15 (31)                | 1.90 (1.29-2.81)    |         |
| Causes of death <sup>a</sup>                 |                            |                        |                     |         |
| Neurologic                                   | 14 (56)                    | 8 (62)                 | 1 [Reference]       | .99     |
| Systemic                                     | 11 (44)                    | 5 (38)                 | 4.23 (1.87-9.58)    |         |
| MRC score at 3 mo, median (IQR) <sup>b</sup> | 60 (53.50-60)              | 60 (47.50-60)          |                     | .95     |
| Hearing impairment at 3 mo <sup>b</sup>      | 8 (42)                     | 3 (20)                 | 3.38 (1.08-10.57)   | .27     |
| Aspiration pneumonia <sup>c</sup>            | 4 (8)                      | 4 (8)                  | 1.02 (0.27-3.85)    | >.99    |
| Hemorrhage <sup>d</sup>                      | 4 (8)                      | 2 (4)                  | 2.00 (0.38-10.41)   | .68     |
| Cardiac arrhythmia <sup>d</sup>              | 12 (25)                    | 7 (15)                 | 1.72 (0.74-3.98)    | .31     |
| Nosocomial pneumonia <sup>d</sup>            | 9 (19)                     | 11 (23)                | 0.82 (0.37-1.79)    | .80     |

Abbreviations: GOS, Glasgow Outcome Scale; IQR, interquartile range; MRC, Medical Research Council.

<sup>a</sup> Causes of death could be determined in 40 patients (25 in the hypothermia group and 15 in the control group).

<sup>b</sup> The MRC score and hearing impairment data were available for 34 survivors (19 in the hypothermia group and 15 in the control group). The MRC scale assesses strength in 3 muscle groups in each arm and leg. The score for each

muscle group ranges from 0 (paralysis) to 5 (normal strength), with the overall score ranging from 0 to 60. Comparisons were made with the Wilcoxon test.

<sup>c</sup> Aspiration pneumonia was evaluated in 97 patients (49 in the hypothermia group and 48 in the control group).

<sup>d</sup> Hemorrhage, cardiac arrhythmia, and nosocomial pneumonia were evaluated in 96 patients (48 in the hypothermia group and 48 in the control group).




outcome at 3 months accounted for 10 of 13 patients (77%) who were cooled with intravascular technique vs 31 of 36 patients (86%) who were cooled with other techniques ( $P = .36$ ). Mortality at 3 months occurred in 6 of 13 patients (46%) who were cooled with intravascular technique vs 14 of 36 patients (40%) who were cooled with other techniques ( $P = .46$ ). Predefined

subgroup analysis on patients with pneumococcal meningitis showed similar results (Table 4).

There were no differences in occurrence of infections, hemorrhage, cardiovascular effects, and hyperglycemia between treatment groups (Table 2 and eFigures 1 and 2 in the Supplement). When evaluated at intensive care unit discharge in 60 of 67 evaluable patients (90%), and at 3 months in 34 of 58 evaluable patients (59%), hearing loss was similar between groups. Intensive care unit and hospital length of stay were longer in the hypothermia group than in the control group (median [IQR], 15 [9-25] days vs 7 [6-15] days;  $P = .006$ ; and 33 [21-42] days vs 20 [14-30] days;  $P = .03$ ; respectively).

Repeated lumbar punctures 3 days after randomization were performed in 14 patients (29%) in the hypothermia group and 11 patients (22%) in the control group, and all cultures were negative; however, CSF leukocyte counts, protein, and glucose concentrations between treatment groups were similar. Patients showing no activity were 6 (17%) in the control group and 3 (9%) in the hypothermia group. For low-amplitude waves, those proportions were 27 (79%) and 29 (88%), respectively, and for spikes and sharp waves were 1 (3%) for each treatment group. No statistical difference on proportions of those abnormal electroencephalography were found (by Fisher test,  $P = .73$ ). For serum sodium concentration, the overall effect of 0.527 (95% CI, -0.003 to 1.06) of the evolution of concentrations on time, evaluated using linear mixed models, was significant between treatment groups ( $P = .0497$ ) (eFigure 3 in the Supplement). No significant difference between the 2 groups with respect to infusion of osmotic agents was found.

**Figure 3. Three-Month Scores on Glasgow Outcome Scale of Patients With Severe Bacterial Meningitis Treated With Hypothermia or Standard Therapy**




**Table 3. Results of the Cox Proportional Hazards Regression Model**

| Variables                             | Hazard Ratio (95% CI) | P Value |
|---------------------------------------|-----------------------|---------|
| Treatment group                       |                       |         |
| Control                               | 1 [Reference]         |         |
| Hypothermia                           | 1.76 (0.89-3.45)      | .10     |
| Age, per 10-y increment               | 1.25 (1.01-1.55)      | .04     |
| Glasgow Coma Scale score at inclusion | 0.89 (0.77-1.02)      | .08     |
| Septic shock                          |                       |         |
| No                                    | 1 [Reference]         |         |
| Yes                                   | 2.54 (1.31-4.94)      | .006    |

**Antibiotic and Anti-inflammatory Treatment**

Ninety-seven patients received microbiologically appropriate antibiotic treatment. The median time between arrival in the emergency department and intravenous administration of antibiotics was 3.0 hours in the hypothermia group and 2.6 hours in the control group. In the hypothermia group, 1 patient had confirmed tuberculous meningitis (positive CSF culture) and received specific medication after 26 days. This pa-

**Figure 4. Kaplan-Meier Estimates of Survival of Patients With Severe Bacterial Meningitis Treated With Hypothermia or Standard Therapy**



Three-month survival curves were compared with a univariate Cox proportional hazards regression model.

Table 4. Outcomes for Patients With Pneumococcal Meningitis at 3 Months (N=75)

| Outcome                                      | No. (%) of Patients        |                        | Risk Ratio (95% CI) | P Value |
|--|----------------------------|------------------------|---------------------|---------|
|  | Hypothermia Group (n = 37) | Control Group (n = 38) |                     |         |
| Unfavorable outcome (score on GOS <5)        | 32 (86)                    | 30 (79)                | 1.04 (0.84-1.28)    | .58     |
| Score on GOS                                 |                            |                        |                     |         |
| 5 = mild or no disability                    | 5 (14)                     | 8 (21)                 | 1 [Reference]       |         |
| 4 = moderate disability                      | 7 (19)                     | 6 (16)                 | 1.00 (0.47-2.16)    |         |
| 3 = severe disability                        | 5 (14)                     | 13 (34)                | 0.18 (0.09-0.37)    | .07     |
| 2 = vegetative state                         | 0                          | 0                      |                     |         |
| 1 = death                                    | 20 (54)                    | 11 (29)                | 2.39 (1.56-3.68)    |         |
| Causes of death <sup>a</sup>                 |                            |                        |                     |         |
| Neurologic                                   | 12 (60)                    | 8 (80)                 | 1 [Reference]       | .42     |
| Systemic                                     | 8 (40)                     | 2 (20)                 | 8.00 (2.07-30.88)   |         |
| MRC score at 3 mo, median (IQR) <sup>b</sup> | 60.00 (48.00-60.00)        | 59.50 (42.50-60.00)    |                     | .53     |
| Hearing impairment at 3 mo                   | 7 (54)                     | 2 (20)                 | 4.55 (1.19-17.34)   | .20     |
| Aspiration pneumonia <sup>c</sup>            | 2 (5)                      | 3 (8)                  | 0.65 (0.12-3.67)    | >.99    |
| Hemorrhage <sup>d</sup>                      | 3 (8)                      | 1 (3)                  | 2.84 (0.31-26.08)   | .35     |
| Cardiac arrhythmia <sup>d</sup>              | 8 (22)                     | 4 (11)                 | 1.90 (0.62-5.75)    | .22     |
| Nosocomial pneumonia <sup>d</sup>            | 4 (11)                     | 9 (24)                 | 0.42 (0.14-1.25)    | .22     |

Abbreviations: GOS, Glasgow Outcome Scale; IQR, interquartile range; MRC, Medical Research Council.

<sup>a</sup> Causes of death could be determined in 30 patients (20 in the hypothermia group and 10 in the control group).

<sup>b</sup> The MRC score and hearing impairment data were available for 23 survivors (13 in the hypothermia group and 10 in the control group). The MRC scale assesses strength in 3 muscle groups in each arm and leg. The score for each

muscle group ranges from 0 (paralysis) to 5 (normal strength), with the overall score ranging from 0 to 60. Comparison was made with the Wilcoxon test.

<sup>c</sup> Aspiration pneumonia was evaluated in 76 patients (37 in the hypothermia group and 39 in the control group).

<sup>d</sup> Hemorrhage, cardiac arrhythmia, and nosocomial pneumonia were evaluated in 74 patients (36 in the hypothermia group and 38 in the control group).

tient died 40 days after randomization because of persistent vegetative state and life support withdrawal. Eighty-seven percent of the patients received corticosteroids in both groups. Thirty-eight patients (78%) in the hypothermia group and 39 patients (81%) in the control group received adjunctive dexamethasone at the recommended dose of 40 mg/d for a maximal duration of 4 days. Hydrocortisone (200 mg/d) was administered in 3 and 5 patients in the hypothermia and control groups, respectively.

## Discussion

In our study on adults with severe bacterial meningitis, which was stopped early by the DSMB, therapeutic hypothermia did not improve outcome in patients with severe bacterial meningitis. Although there was a trend toward higher mortality and rate of unfavorable outcome in the hypothermia group, early stopping of clinical trials is known to exaggerate treatment effects,<sup>30,31</sup> precluding firm conclusions about harm of therapeutic hypothermia in bacterial meningitis.

Potential mechanisms behind this clinically relevant mortality difference remain unclear. We found no difference in nosocomial infections, hemorrhage, cardiovascular effects, or hyperglycemia between the treatment groups. There was a difference in median serum sodium concentrations between the treatment groups. Hypernatremia on admission has been described to be associated with unfavorable outcome in bacterial meningitis,<sup>32</sup> but, in our study group, order changed after

2 days and the influence of median sodium levels on outcome of bacterial meningitis over time is unknown. The relatively small difference between serum sodium concentrations found between groups over time more likely results from the detrimental condition of patients included in the hypothermia group than from rapid cold saline infusion. However, outcomes between patients receiving higher vs lower volume cold saline to induce hypothermia were similar. In addition, because each center included a small number of patients, it was difficult to identify any center effect in the statistical analysis.

Septic shock has been associated with unfavorable outcome in bacterial meningitis,<sup>1</sup> and the proportion of this condition was somewhat higher in the hypothermia group than in the control group (47% vs 32%, respectively). The relative low dose of corticosteroids, recommended by several experts,<sup>2</sup> administered to patients with septic shock, could introduce a bias toward a higher mortality in the hypothermia group because early treatment with high-dose dexamethasone reduces the mortality in adults with bacterial meningitis.<sup>4</sup> The proportion of patients treated with high-dose corticosteroids between treatment groups in our study was similar, indicating that a difference in corticosteroid therapy did not confound the results. The use of high-dose corticosteroids in patients with meningitis and septic shock is in line with a recent advisement, stating that the survival benefit in patients with pneumococcal meningitis who were administered adjunctive dexamethasone outweighs the risks associated with high-dose corticosteroids in this population.<sup>6</sup>

The results of our study are in contrast with those concerning global cerebral hypoxia, in which beneficial effects of hypothermia were reported.<sup>12-14</sup> Studies in animals have also demonstrated therapeutic value of hypothermia in bacterial meningitis,<sup>7,9,10,33,34</sup> and observational studies reported favorable effects of hypothermia in adults with severe pneumococcal meningitis.<sup>19</sup> In bacterial meningitis, the actual time of the assault is difficult to assess, which might result in a more heterogeneous cerebral disorder than in cardiac arrest or neonatal hypoxic-ischemic encephalopathy.<sup>35</sup> Our findings are more in line with traumatic brain injury, where the effect of hypothermia is controversial.<sup>11,16</sup> Our study is one of the few randomized controlled studies in critically ill patients with bacterial meningitis. The mortality rate among patients in the control group (31%) was consistent with previously reported studies,<sup>4,5,36</sup> indicating that selection bias was not a matter of great concern.

Post hoc futility analysis showed how small the likelihood was of the study finding a results favoring hypothermia if it had proceed to completion, thereby supporting the advice of the DSMB to terminate the study early. Terminated early, our study has low statistical power, precluding robust subgroup analysis and assertion of a smaller harm effect of hypothermia.<sup>37,38</sup> For hypothermia treatment, total blinding was not feasible, but a physician who was blinded for treatment regimens assessed the primary end point, according to the Prospective Open Blinded Endpoint methodology. Although associated with high mortality and morbidity, bacterial meningitis is a relatively rare disease in high-income countries.<sup>39</sup> Because only the most severely ill patients with bacterial meningitis could be included in our study, many centers were needed to include our intended number of patients. We advised to treat all enrolled patients according to guidelines and many clinicians followed these recommendations (eAppendix 1 in the Supplement).

A limitation of our study is the heterogeneity of timeline from disease onset to treatment. This onset is much more difficult to determine compared with cardiac arrest and traumatic brain injury. Moreover, although the median time to target temperature was relatively short (4.4 hours), the timeline was quite variable among patients. Because each enrolling hospital performed cooling in their local method of choice, there was some heterogeneity of targeted hypothermia. However, to date, no technique has been proved to be associated with a better outcome in cardiac arrest. In our study, we did not observe any differences on outcome according to cooling techniques (endovascular vs other techniques, such as ice packs, cooling blanket, cooling pads, or cooling mattress).

Traumatic brain injury studies have evaluated duration of hypothermia ranging from 24 hours to 7 days. We chose to treat patients with hypothermia for 48 hours because the majority of hypothermia studies used this time frame, and CSF cultures in patients with pneumococcal meningitis have been reported to be negative after 24 hours of treatment.<sup>2</sup> The complexity of the patient population and relatively limited funding precluded confirmation that CSF inflammatory biomarker reduction was consistent with animal studies. We also did not evaluate intracranial pressure because this is not considered standard practice.<sup>6</sup>

## Conclusion

In conclusion, our trial does not support the use of hypothermia in adults with severe meningitis. Moderate hypothermia did not improve outcome in patients with severe bacterial meningitis and may even be harmful. Our results may have important implications for future trials on hypothermia in patients presenting with septic shock or stroke. Careful evaluation of safety issues in these future and ongoing trials are needed.

### ARTICLE INFORMATION

**Published Online:** October 8, 2013.  
doi:10.1001/jama.2013.280506.

**Author Affiliations:** Réanimation Médicale et Infectieuse, Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Bichat-Claude Bernard, Université Paris Diderot, Sorbonne Paris Cité, Paris, France (Mourvillier, Wolff); Département d'Epidémiologie et Recherche Clinique, Assistance Publique-Hôpitaux de Paris Hôpital Bichat, INSERM, CIE 801, Université Paris Diderot, Sorbonne Paris Cité, Paris, France (Tubach, Esposito-Farèse); Department of Neurology, Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands (van de Beek); Service de Réanimation Médicale, Centre Hospitalier Universitaire de Tours-Hôpital Bretonneau, Tours, France (Garot); Réanimation Médico-Chirurgicale, Centre Hospitalier Universitaire Dupuytren, Limoges Cedex, Cedex, France (Pichon); Réanimation Polyvalente et Maladies Infectieuses, Centre Hospitalier Universitaire de Tourcoing, Tourcoing, France (Georges); Centre Hospitalier Départemental Les Oudaries, Service de Réanimation Polyvalente, La Roche-sur-Yon, France

(Lefevre); Centre Hospitalier Universitaire de Nancy, Hôpital Central, Service de Réanimation Médicale, Nancy, France (Bollaert); Service de Réanimation Polyvalente, Centre Hospitalier Régional Orléans, Orléans, France (Boullain); Service de Réanimation Médico-Chirurgicale, Centre Hospitalier Universitaire Jean Verdier, Assistance Publique-Hôpitaux de Paris, Bondy, France (Luis); Service de Réanimation Médicale, Paris, France, Centre Hospitalier Universitaire Cochin-Saint-Vincent de Paul-Site Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France (Cariou); Service de Réanimation Polyvalente, Centre Hospitalier Régional Universitaire de Lille-Hôpital Roger Salengro, Lille, France (Girardie); Service de Réanimation Polyvalente, Centre Hospitalier Intercommunal André Grégoire Montreuil, Montreuil, France (Chelha); Service de Réanimation Médicale et Toxicologique, Centre Hospitalier Universitaire Lariboisière Assistance Publique-Hôpitaux, Paris, France (Megarbane); Service de Réanimation Polyvalente, Centre Hospitalier, Rodez, France (Delahaye); Service de Réanimation Médico-Chirurgicale, Assistance Publique-Hôpitaux de Paris, Centre Hospitalier Universitaire Tenon, Paris, France (Chalumeau-Lemoine); Service de

Réanimation, Centre Hospitalier de Versailles, Le Chesnay, France (Legriél); Service de Réanimation Médico-Chirurgicale, Centre Hospitalier, Roanne, France (Beuret); Réanimation Médicale Centre Hospitalier Universitaire Antoine Beclère, Assistance Publique-Hôpitaux de Paris, Clamart, France (Brivet); Service de Réanimation Polyvalente, Groupe Hospitalier Paris Saint-Joseph, Paris, France (Bruel); Réanimation Médicale, Hôpital Saint André, Centre Hospitalier Universitaire, Bordeaux, France (Camou); Service de Réanimation Médicale, Centre Hospitalier Universitaire, Poitiers, France (Chatellier); Service de Réanimation Polyvalente, Centre Hospitalier, Châlons-en-Champagne, France (Chillet); Service de Réanimation Médico-Chirurgicale, Assistance Publique-Hôpitaux de Paris, Garches, France (Clair); Service de Réanimation Adultes and USC, Centre Hospitalier Universitaire Estaing, Clermont-Ferrand, France (Constantin); Service de Pneumologie et Réanimation Médicale, Centre Hospitalier Universitaire La Pitié-Salpêtrière Assistance Publique-Hôpitaux de Paris, Paris, France (Duguet); Réanimation Polyvalente, Hôpital Foch, Suresnes, France (Galliot); Service de Réanimation Médicale et Respiratoire, Centre Hospitalier Universitaire Hôpital de la Croix Rousse, Lyon, France (Bayle);



Service de Réanimation Médicale, Hôpital de l'Archet, Nice, France (Hyvemat); Réanimation Polyvalente, Les Hôpitaux de Chartres, Chartres, France (Ouchenir); Service de Réanimation Polyvalente, Centre Hospitalier, d'Argenteuil, France (Plantefevre); Service de Réanimation Médicale, Centre Hospitalier Universitaire, Dijon, France (Quenot); Service de Réanimation Médico-Chirurgicale, CH René Dubos, Pontoise, France (Richecoeur); Service de Réanimation Médicale, Centre Hospitalier Universitaire Hôpital A. Michallon, La Tronche, France (Schwebel); Service de Réanimation Polyvalente, Centre Hospitalier de la Région d'Annecy, Pringy, France (Sirodot); Service de Réanimation Médicale et Infectieuse, Centre Hospitalier Universitaire Hôpital Pontchaillou, Rennes, France (Le Tulzo).

**Author Contributions:** Drs Tubach and Esposito-Farèse had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Tubach and van de Beek contributed equally to the manuscript.

**Study concept and design:** Mourvillier, Tubach, van de Beek, Cariou, Le Tulzo, Wolff.

**Acquisition of data:** Mourvillier, Garot, Pichon, Georges, Martin-Lefevre, Bollaert, Boulain, Luis, Cariou, Girardie, Chelha, Megarbane, Delahaye, Chalumeau-Lemoine, Legriell, Beuret, Brivet, Bruel, Camou, Chatellier, Chillet, Clair, Constantin, Duguet, Galliot, Bayle, Hyvemat, Ouchenir, Plantefevre, Richecoeur, Sirodot, Le Tulzo, Wolff.

**Analysis and interpretation of data:** Mourvillier, Tubach, van de Beek, Boulain, Quenot, Richecoeur, Schwebel, Esposito-Farèse, Wolff.

**Drafting of the manuscript:** Mourvillier, Tubach, van de Beek, Martin-Lefevre, Chelha, Chatellier, Chillet, Duguet, Galliot, Wolff.

**Critical revision of the manuscript for important intellectual content:** Mourvillier, Tubach, van de Beek, Garot, Pichon, Georges, Bollaert, Boulain, Luis, Cariou, Girardie, Megarbane, Delahaye, Chalumeau-Lemoine, Legriell, Beuret, Brivet, Bruel, Camou, Clair, Constantin, Bayle, Hyvemat, Ouchenir, Plantefevre, Quenot, Richecoeur, Schwebel, Sirodot, Esposito-Farèse, Le Tulzo, Wolff.

**Statistical analysis:** Tubach, Esposito-Farèse.

**Obtained funding:** Mourvillier, Tubach.

**Administrative, technical, or material support:** Mourvillier, Tubach, Garot, Martin-Lefevre, Bollaert, Luis, Chalumeau-Lemoine, Clair, Ouchenir, Quenot, Richecoeur, Wolff.

**Study supervision:** Mourvillier, Tubach, van de Beek, Girardie, Constantin, Wolff.

**Conflict of Interest Disclosures:** All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

**Funding/Support:** This work was funded by a research grant from the French Ministry of Health (Programme Hospitalier de Recherche Clinique PHRC-AOM06038) and by unrestricted grants from IST Cardiology and Covidien companies. IST Cardiology provided endovascular catheters and cooling devices for 12 centers at decreased rates. Covidien provided free esophageal temperature probes for all included patients. Dr van de Beek was supported by grants 917.11.358 from the Netherlands Organization for Health Research and Development and 281156 from the European Research Council. The sponsor was the

Département à la Recherche Clinique et au Développement, Assistance Publique-Hôpitaux de Paris.

**Role of the Sponsors:** None of the sponsors had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Data Monitoring:** Lucile Collas, Caroline Quintin (INSERM, CIE 801, and URC Paris Nord).

**Data and Safety Monitoring Board:** A. Mercat (Réanimation Médicale, Angers); G. Capellier (Réanimation Médicale, Besançon); S. Jaber (DAR, Montpellier). Members of the data and safety monitoring board were masked to treatment allocations (ie, they had only knowledge of A or B group; they asked for unblinding at the second data and safety monitoring board meeting due to the statistically significant difference in mortality) and reviewed all data on primary outcome, mortality, and serious adverse events. They were independent and had no conflict of interest with investigators, the sponsor, or manufacturers of cooling devices.

**Participating Centers:** Centre Hospitalier Intercommunal Côte Basque, Bayonne (W. Marie); Centre Hospitalier, Beauvais (A.M. Guerin); Centre Hospitalier Belfort Montbéliard, Belfort (O. Ruyer); Centre Hospitalier Universitaire de la Cavale Blanche, Brest (J.M. Tonnelier); Centre Hospitalier Universitaire A. Beclère, Clamart (F. Jacobs, P. Lafforgue, D. prat, C. Pilorge); Hôpital G. Montpied, Clermont-Ferrand (A. Ait Hssain); Centre Hospitalier Universitaire Hotel Dieu, Clermont-Ferrand (M. Jabaudon); Centre Hospitalier de Dreux, Dreux (M. Boudon); Centre Hospitalier Gonesse, Gonesse (D. Toledano-Goldgran); Centre Hospitalier Départemental Les Oudairies, La Roche sur Yon (E. Clementi, I. Vinatier, M. Fiancette, G. Belliard, B. Renard, J. Reigier); Centre Hospitalier Universitaire Croix Rousse, Lyon (C. Guerin, V. Leray); Centre Hospitalier Universitaire Gui de Chauviac, Montpellier (P. Corne); Hôpital Central, Nancy (D. Barraud, A. Cravoisy-Popovic, M. Conrad, S. Gibot, F. Hein, L. Nace); Centre Hospitalier Universitaire Saint Roch, Nice (S. Gindre, H. Quintard); Hôpital de La Source, Orleans (D. Benzeki, A. Bretagnol, A. Marthonnet, I. Runge, M. Skarzynski); Centre Hospitalier Universitaire Bicêtre, Le Kremlin Bicêtre (D. Osman, C. Richard); Centre Hospitalier Universitaire Bichat, Paris (L. Bouadma); Centre Hospitalier Universitaire Cochin, Paris (J. Charpentier, J-D. Chiche, N. Demars, J. Fichet, N. Marin, J-P. Mira, B. Vandenbunder); Hôpital des Diaconesses, Paris (F. Thomas); Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris (J. Mayaux, H. Prodanovic); Centre Hospitalier Universitaire Saint-Antoine, Paris (J-L. Baudel); Centre Hospitalier Universitaire Tenon, Paris (M. Djibré, M. Fartoukh); Centre Hospitalier Poissy-Saint Germain, Poissy (J-C. Lacherade); Hôpital R. Dubos, Pontoise (E. Colin, D. Combaux); Hôpital C. Gallien, Quincy sous Senart (J-F. Angellier); Hôpital Pontchaillou, Rennes (A. Gros, S. Isslame); Centre Hospitalier Poissy-Saint Germain, Saint Germain-en-Laye (J-L. Ricome); Centre Hospitalier Universitaire Hautepierre, Strasbourg (V. Castelain); Hôpital Foch, Suresnes (C. Cerf); Centre Hospitalier de Bigorre, Tarbes (P. Pinta); Centre Hospitalier Universitaire Tourcoing,

Tourcoing (N. Boussekey, A. Chiche, O. Leroy, A. Meybeck); Hôpital A. Mignot, Versailles (J.P. Bédos, F. Bruneel, G. Troché); Centre Hospitalier de Chambéry, Chambéry (M. Badet, C. Chastagner, B. Zerr).

**Additional Contributions:** Kimberly Cox, PhD (Massachusetts General Hospital, Reproductive Endocrine Unit, Boston, Massachusetts), provided medical writing assistance on the manuscript and received financial compensation.

## REFERENCES

- van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. *N Engl J Med*. 2004;351(18):1849-1859.
- van de Beek D, de Gans J, Tunkel AR, Wijdicks EF. Community-acquired bacterial meningitis in adults. *N Engl J Med*. 2006;354(1):44-53.
- Auburtin M, Wolff M, Charpentier J, et al. Detrimental role of delayed antibiotic administration and penicillin-nonsusceptible strains in adult intensive care unit patients with pneumococcal meningitis: the PNEUMOREA prospective multicenter study. *Crit Care Med*. 2006;34(11):2758-2765.
- de Gans J, van de Beek D; European Dexamethasone in Adulthood Bacterial Meningitis Study Investigators. Dexamethasone in adults with bacterial meningitis. *N Engl J Med*. 2002;347(20):1549-1556.
- Brouwer MC, Heckenberg SGB, de Gans J, Spanjaard L, Reitsma JB, van de Beek D. Nationwide implementation of adjunctive dexamethasone therapy for pneumococcal meningitis. *Neurology*. 2010;75(17):1533-1539.
- van de Beek D, Brouwer MC, Thwaites GE, Tunkel AR. Advances in treatment of bacterial meningitis. *Lancet*. 2012;380(9854):1693-1702.
- Angstwurm K, Reuss S, Freyer D, et al. Induced hypothermia in experimental pneumococcal meningitis. *J Cereb Blood Flow Metab*. 2000;20(5):834-838.
- Irazuzta JE, Pretzlaff RK, Zingarelli B, Xue V, Zemlan F. Modulation of nuclear factor-kappaB activation and decreased markers of neurological injury associated with hypothermic therapy in experimental bacterial meningitis. *Crit Care Med*. 2002;30(11):2553-2559.
- Irazuzta JE, Olson J, Kiefaber MP, Wong H. Hypothermia decreases excitatory neurotransmitter release in bacterial meningitis in rabbits. *Brain Res*. 1999;847(1):143-148.
- Xu L, Yenari MA, Steinberg GK, Giffard RG. Mild hypothermia reduces apoptosis of mouse neurons in vitro early in the cascade. *J Cereb Blood Flow Metab*. 2002;22(1):21-28.
- Nunnally ME, Jaeschke R, Bellingan GJ, et al. Targeted temperature management in critical care: a report and recommendations from five professional societies. *Crit Care Med*. 2011;39(5):1113-1125.
- Bernard SA, Gray TW, Buist MD, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. *N Engl J Med*. 2002;346(8):557-563.
- Hypothermia After Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the

- neurologic outcome after cardiac arrest. *N Engl J Med*. 2002;346(8):549-556.
14. Shankaran S, Laptook AR, Ehrenkranz RA, et al; National Institute of Child Health and Human Development Neonatal Research Network. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. *N Engl J Med*. 2005;353(15):1574-1584.
  15. Gluckman PD, Wyatt JS, Azzopardi D, et al. Selective head cooling with mild systemic hypothermia after neonatal encephalopathy: multicentre randomised trial. *Lancet*. 2005;365(9460):663-670.
  16. Clifton GL, Miller ER, Choi SC, et al. Lack of effect of induction of hypothermia after acute brain injury. *N Engl J Med*. 2001;344(8):556-563.
  17. McIntyre LA, Fergusson DA, Hébert PC, Moher D, Hutchison JS. Prolonged therapeutic hypothermia after traumatic brain injury in adults: a systematic review. *JAMA*. 2003;289(22):2992-2999.
  18. Cuthbertson BH, Dickson R, Mackenzie A. Intracranial pressure measurement, induced hypothermia and barbiturate coma in meningitis associated with intractable raised intracranial pressure. *Anaesthesia*. 2004;59(9):908-911.
  19. Lepur D, Kutleša M, Baršić B. Induced hypothermia in adult community-acquired bacterial meningitis: more than just a possibility? *J Infect*. 2011;62(2):172-177.
  20. Polderman KH, Rijnsburger ER, Peerdeman SM, Girbes AR. Induction of hypothermia in patients with various types of neurologic injury with use of large volumes of ice-cold intravenous fluid. *Crit Care Med*. 2005;33(12):2744-2751.
  21. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. *Clin Infect Dis*. 2004;39(9):1267-1284.
  22. [17th Consensus conference. Consensus conference on bacterial meningitis. Short text]. *Med Mal Infect*. 2009;39(3):175-186.
  23. Jennett B, Bond M. Assessment of outcome after severe brain damage. *Lancet*. 1975;1(7905):480-484.
  24. Hansson L, Hedner T, Dahlöf B. Prospective Randomized Open Blinded End-Point (PROBE) study: a novel design for intervention trials. *Blood Press*. 1992;1(2):113-119.
  25. Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the extended Glasgow Outcome Scale: guidelines for their use. *J Neurotrauma*. 1998;15(8):573-585.
  26. Fayol P, Carrière H, Habonimana D, Preux PM, Dumond JJ. [French version of structured interviews for the Glasgow Outcome Scale: guidelines and first studies of validation]. *Ann Readapt Med Phys*. 2004;47(4):142-156.
  27. Pirozzo S, Papinczak T, Glasziou P. Whispered voice test for screening for hearing impairment in adults and children: systematic review. *BMJ*. 2003;327(7421):967.
  28. Weisfelt M, van de Beek D, Spanjaard L, Reitsma JB, de Gans J. Clinical features, complications, and outcome in adults with pneumococcal meningitis: a prospective case series. *Lancet Neurol*. 2006;5(2):123-129.
  29. Whitehead J. *The Design and Analysis of Sequential Clinical Trials*. Hoboken, NJ: John Wiley & Sons; 1997.
  30. Bassler D, Briel M, Montori VM, et al; STOPIT-2 Study Group. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. *JAMA*. 2010;303(12):1180-1187.
  31. Montori VM, Devereaux PJ, Adhikari NK, et al. Randomized trials stopped early for benefit: a systematic review. *JAMA*. 2005;294(17):2203-2209.
  32. van de Beek D, Brouwer M, de Gans J. Hypernatremia in bacterial meningitis. *J Infect*. 2007;55(4):381-382.
  33. Irazuzta JE, Pretzlaff R, Rowin M, Milam K, Zemlan FP, Zingarelli B. Hypothermia as an adjunctive treatment for severe bacterial meningitis. *Brain Res*. 2000;881(1):88-97.
  34. Rowin ME, Xue V, Irazuzta J. Hypothermia attenuates beta1 integrin expression on extravasated neutrophils in an animal model of meningitis. *Inflammation*. 2001;25(3):137-144.
  35. Mook-Kanamori BB, Geldhoff M, van der Poll T, van de Beek D. Pathogenesis and pathophysiology of pneumococcal meningitis. *Clin Microbiol Rev*. 2011;24(3):557-591.
  36. Brouwer MC, McIntyre P, Prasad K, van de Beek D. Corticosteroids for acute bacterial meningitis. *Cochrane Database Syst Rev*. 2013;6:CD004405.
  37. Iltis AS. Stopping trials early for commercial reasons: the risk-benefit relationship as a moral compass. *J Med Ethics*. 2005;31(7):410-414.
  38. Silverman H. Ethical issues during the conduct of clinical trials. *Proc Am Thorac Soc*. 2007;4(2):180-184.
  39. McIntyre PB, O'Brien KL, Greenwood B, van de Beek D. Effect of vaccines on bacterial meningitis worldwide. *Lancet*. 2012;380(9854):1703-1711.